{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:52:31Z","timestamp":1792003951647,"version":"4.4.0"},"reference-count":183,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Leukemia is a malignancy of the bone marrow and blood resulting from the abnormal differentiation of hematopoietic stem cells (HSCs). There are four main types of leukemia including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL). While chemotherapy and radiation have been conventional forms of treatment for leukemia, these therapies increase infection susceptibility, adverse side effects and immune cell inactivation. Immunotherapies are becoming promising treatment options for leukemia, with natural killer (NK) cell-mediated therapy providing a specific direction of interest. The role of NK cells is critical for cancer cell elimination as these immune cells are the first line of defense against cancer proliferation and are involved in both recognition and cytolysis of rapidly dividing and abnormal cell populations. NK cells possess various activating and inhibitory receptors, which regulate NK cell function, signaling either inhibition and continued surveillance, or activation and subsequent cytotoxic activity. In this review, we describe NK cells and NK cell receptors, functional impairment of NK cells in leukemia, NK cell immunotherapies currently under investigation, including monoclonal antibodies (mAbs), adoptive transfer, chimeric antigen receptor-NKs (CAR-NKs), bi-specific\/tri-specific killer engagers (BiKEs\/TriKEs) and future potential targets of NK cell-based immunotherapy for leukemia.<\/jats:p>","DOI":"10.3390\/cancers14030843","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T01:03:40Z","timestamp":1644368620000},"page":"843","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Natural Killer Cell-Mediated Immunotherapy for Leukemia"],"prefix":"10.3390","volume":"14","author":[{"given":"Michaela","family":"Allison","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology & Genetics, UNT Health Science Center, Fort Worth, TX 76107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Mathews","sequence":"additional","affiliation":[{"name":"Texas College of Osteopathic Medicine, UNT Health Science Center, Fort Worth, TX 76107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Gilliland","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Sports Therapy and Research at The STAR, Frisco, TX 75034, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5784-224X","authenticated-orcid":false,"given":"Stephen O.","family":"Mathew","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology & Genetics, UNT Health Science Center, Fort Worth, TX 76107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12070","DOI":"10.1038\/s41598-019-48445-1","article-title":"An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States","volume":"9","author":"Hao","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_2","unstructured":"(2021, December 27). Statistics on Leukemia and Other Blood Cancers. Available online: https:\/\/allbloodcancers.org\/statistics\/."},{"key":"ref_3","unstructured":"(2021, December 27). Cancer Facts and Figures. Available online: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2021.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","article-title":"New directions for emerging therapies in acute myeloid leukemia: The next chapter","volume":"10","author":"Daver","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e26489","DOI":"10.1002\/pbc.26489","article-title":"Health-related quality of life of children on treatment for acute lymphoblastic leukemia: A systematic review","volume":"64","author":"Fardell","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e2014005","DOI":"10.4084\/mjhid.2014.005","article-title":"Treatment recommendations for chronic myeloid leukemia","volume":"6","author":"Baccarani","year":"2014","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s13244-015-0417-x","article-title":"Chemotherapy-related complications in the kidneys and collecting system: An imaging perspective","volume":"6","author":"Jia","year":"2015","journal-title":"Insights Into Imaging"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/path.5389","article-title":"Radiation-induced tissue damage and response","volume":"250","author":"McBride","year":"2020","journal-title":"J. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13287-021-02277-x","article-title":"Natural killer cell therapy for hematologic malignancies: Successes, challenges, and the future","volume":"12","author":"Lamb","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3322\/caac.21235","article-title":"Cancer treatment and survivorship statistics, 2014","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fonc.2019.00917","article-title":"Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer","volume":"9","author":"Shang","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.smim.2017.07.009","article-title":"NK cell-based immunotherapy for cancer","volume":"31","author":"Fang","year":"2017","journal-title":"Semin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41434-021-00246-w","article-title":"Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany","volume":"28","author":"Albinger","year":"2021","journal-title":"Gene Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000447076","article-title":"Leukemia","volume":"43","author":"Juliusson","year":"2016","journal-title":"Prog. Tumor. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11910-017-0726-1","article-title":"Neurological Complications of the Leukemias Across the Ages","volume":"17","author":"Berg","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_16","unstructured":"Lyengar, V.S.A. (2021). Leukemia, StatPearls Publishing."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12935-021-01746-w","article-title":"Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: Towards precision medicine overcoming drug resistance","volume":"21","author":"Levin","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s43018-020-00124-1","article-title":"Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia","volume":"1","author":"Oshima","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sheykhhasan, M., Manoochehri, H., and Dama, P. (2022). Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: A review study. Cancer Gene Ther., 1\u201317.","DOI":"10.1038\/s41417-021-00418-1"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: Recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3389\/fimmu.2019.02357","article-title":"Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells","volume":"10","author":"Carlsten","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Arruga, F., Gyau, B.B., Iannello, A., Vitale, N., Vaisitti, T., and Deaglio, S. (2020). Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051825"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/pbc.25555","article-title":"Natural killer cell therapy in children with relapsed leukemia","volume":"62","author":"Rubnitz","year":"2015","journal-title":"Pediatric Blood Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.bbmt.2010.01.019","article-title":"Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade","volume":"16","author":"Godal","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41375-021-01349-4","article-title":"Decrease post-transplant relapse using donor-derived expanded NK-cells","volume":"36","author":"Ciurea","year":"2022","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ferrara, F., Lessi, F., Vitagliano, O., Birkenghi, E., and Rossi, G. (2019). Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia. Cancers, 11.","DOI":"10.3390\/cancers11020224"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of Relapsed Acute Myeloid Leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-020-00996-x","article-title":"Natural killer cell-based immunotherapy for acute myeloid leukemia","volume":"13","author":"Xu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_31","unstructured":"Vachani, C. (2021, December 27). All About Chronic Myeloid Leukemia (CML); 2019. Available online: https:\/\/www.oncolink.org\/cancers\/leukemia\/chronic-myelogenous-leukemia-cml\/all-about-chronic-myeloid-leukemia-cml."},{"key":"ref_32","unstructured":"(2021, December 27). Key Statistics for Chronic Myeloid Leukemia; 2021. Available online: https:\/\/www.cancer.org\/cancer\/chronic-myeloid-leukemia\/about\/statistics.html."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00411-013-0507-4","article-title":"Sex differences in the incidence of chronic myeloid leukemia","volume":"53","author":"Radivoyevitch","year":"2014","journal-title":"Radiat. Environ. Biophys."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-line therapy for chronic myeloid leukemia: Current status and future directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Guti\u00e9rrez, V., and Hern\u00e1ndez-Boluda, J.C.C. (2020). Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072251"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape","volume":"35","author":"Hsieh","year":"2021","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.3389\/fimmu.2018.03152","article-title":"NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia","volume":"9","author":"Chang","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kim, N., Kim, M.-Y., Cho, Y.-U., Chen, W., Lee, K.-H., and Kim, H.S. (2020). PVR and ICAM-1 on Blast Crisis CML Stem and Progenitor Cells with TKI Resistance Confer Susceptibility to NK Cells. Cancers, 12.","DOI":"10.3390\/cancers12071923"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-142062","article-title":"A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy","volume":"136","author":"Rein","year":"2020","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ped.13457","article-title":"Treatment and biology of pediatric acute lymphoblastic leukemia","volume":"60","author":"Kato","year":"2018","journal-title":"Pediatr. Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2162-3619-3-16","article-title":"Childhood B-acute lymphoblastic leukemia: A genetic update","volume":"3","author":"Woo","year":"2014","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"639479","DOI":"10.3389\/fped.2021.639479","article-title":"The Prenatal Origin of Childhood Leukemia: Potential Applications for Epidemiology and Newborn Screening","volume":"9","author":"Marcotte","year":"2021","journal-title":"Front. Pediatrics"},{"key":"ref_43","first-page":"31","article-title":"Acute Lymphocytic Leukemia in Adults. Pathologic Features and Prognosis","volume":"53","author":"Marinescu","year":"2015","journal-title":"Rom. J. Intern. Med."},{"key":"ref_44","unstructured":"(2021, December 27). Childhood Acute Lymphoblastic Leukemia Treatment, Available online: https:\/\/www.cancer.gov\/types\/leukemia\/hp\/child-all-treatment-pdq#_AboutThis_1."},{"key":"ref_45","first-page":"3596983","article-title":"NK Cells as Possible Prognostic Factor in Childhood Acute Lymphoblastic Leukemia","volume":"2019","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_46","unstructured":"(2017). Chronic lymphocytic leukaemia. Nat. Rev. Dis. Primers, 3, 16099."},{"key":"ref_47","first-page":"379","article-title":"Chronic lymphocytic leukaemia","volume":"46","author":"Karmiris","year":"1991","journal-title":"Br. J. Hosp. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41408-018-0131-2","article-title":"Chronic lymphocytic leukemia treatment algorithm 2018","volume":"8","author":"Parikh","year":"2018","journal-title":"Blood cancer J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"19398","DOI":"10.1038\/s41598-020-76051-z","article-title":"Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance","volume":"10","author":"Calvo","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Hofland, T., Eldering, E., Kater, A.P., and Tonino, S.H. (2019). Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174315"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural Killer Cells: Development, Maturation, and Clinical Utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: An important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/1521-4141(200205)32:5<1205::AID-IMMU1205>3.0.CO;2-Y","article-title":"Human natural killer cells: Their origin, receptors and function","volume":"32","author":"Moretta","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4049\/jimmunol.179.1.89","article-title":"CD56bright human NK cells differentiate into CD56dim cells: Role of contact with peripheral fibroblasts","volume":"179","author":"Chan","year":"2007","journal-title":"J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11357","DOI":"10.1073\/pnas.1815756115","article-title":"Natural killer cells might adapt their in.nhibitory receptors for memory","volume":"115","author":"Cooper","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-0-387-09789-3_4","article-title":"Natural killer cell receptors","volume":"640","author":"Biassoni","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/nri1863","article-title":"Self-tolerance of natural killer cells","volume":"6","author":"Raulet","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1615\/CritRevOncog.2014010805","article-title":"Positive and negative regulation by NK cells in cancer","volume":"19","author":"Sungur","year":"2014","journal-title":"Crit. Rev. Oncog."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fimmu.2017.00292","article-title":"Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation","volume":"8","author":"Wieczorek","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00251-015-0869-7","article-title":"The evolution of natural killer cell receptors","volume":"68","year":"2016","journal-title":"Immunogenetics"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood-2008-05-156836","article-title":"The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells","volume":"113","author":"Brodin","year":"2009","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2009-08-238469","article-title":"Regulation of human NK-cell cytokine and chemokine production by target cell recognition","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","article-title":"The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2141.2001.02906.x","article-title":"Non-MHC-restricted cytotoxic cells: Their roles in the control and treatment of leukaemias","volume":"114","author":"Lowdell","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_66","first-page":"259","article-title":"Natural killer cell-based immunotherapy: From transplantation toward targeting cancer stem cells","volume":"234","author":"Rokni","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","article-title":"NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)","volume":"121","author":"Romee","year":"2013","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3389\/fimmu.2018.02040","article-title":"NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy","volume":"9","author":"Schmiedel","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41392-020-00348-8","article-title":"Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy","volume":"5","author":"Cao","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_70","first-page":"2064","article-title":"Role of NKG2D and its ligands in cancer immunotherapy","volume":"9","author":"Liu","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"ref_71","first-page":"408","article-title":"NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: Role in the NK cell-mediated negative regulation of T cell responses","volume":"3","author":"Zingoni","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Brodsk\u00e1, B., Otev\u0159elov\u00e1, P., \u0160\u00e1lek, C., Fuchs, O., Ga\u0161ov\u00e1, Z., and Ku\u017eelov\u00e1, K. (2019). High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112823"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3389\/fimmu.2020.01710","article-title":"PD-L1 Is Expressed and Promotes the Expansion of Regulatory T Cells in Acute Myeloid Leukemia","volume":"11","author":"Dong","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1158\/2159-8290.CD-18-1259","article-title":"The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector","volume":"9","author":"Dong","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"97671","DOI":"10.18632\/oncotarget.18311","article-title":"Soluble PD-1 and PD-L1: Predictive and prognostic significance in cancer","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.autrev.2018.01.018","article-title":"The SLAM family receptors: Potential therapeutic targets for inflammatory and autoimmune diseases","volume":"17","author":"Dragovich","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2019.00909","article-title":"The Natural Cytotoxicity Receptors in Health and Disease","volume":"10","author":"Barrow","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fimmu.2017.00369","article-title":"Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions with Diverse Ligands and Alterations in Splice Variant Expression","volume":"8","author":"Pazina","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.4049\/jimmunol.1102267","article-title":"Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44","volume":"187","author":"Rosental","year":"2011","journal-title":"J. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12026-015-8695-4","article-title":"Natural killer cell receptors: Alterations and therapeutic targeting in malignancies","volume":"64","year":"2016","journal-title":"Immunol. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3389\/fimmu.2019.01179","article-title":"Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation","volume":"10","author":"Pende","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cyto.b.21508","article-title":"Markers and function of human NK cells in normal and pathological conditions","volume":"92","author":"Marcenaro","year":"2017","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Buller, C.W., Mathew, P.A., and Mathew, S.O. (2020). Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer. Cancers, 12.","DOI":"10.3390\/cancers12071755"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3389\/fimmu.2017.00930","article-title":"Developmental and Functional Control of Natural Killer Cells by Cytokines","volume":"8","author":"Wu","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: From tumor initiation to metastatic progression","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.it.2017.04.004","article-title":"Mechanisms of Immune Tolerance in Leukemia and Lymphoma","volume":"38","author":"Curran","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/jnci\/djt184","article-title":"MHC class I antigen processing and presenting machinery: Organization, function, and defects in tumor cells","volume":"105","author":"Leone","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00262-016-1947-x","article-title":"Rejection versus escape: The tumor MHC dilemma","volume":"66","author":"Garrido","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJM199810223391701","article-title":"Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program","volume":"339","author":"Sasazuki","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.leu.2402865","article-title":"HLA-DR antigen-negative acute myeloid leukemia","volume":"17","author":"Wetzler","year":"2003","journal-title":"Leukemia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nature01112","article-title":"Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation","volume":"419","author":"Groh","year":"2002","journal-title":"Nature"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"31959","DOI":"10.18632\/oncotarget.16657","article-title":"Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition","volume":"8","author":"Raneros","year":"2017","journal-title":"Oncotarget"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"M\u00fcller, R., Misund, K., Holien, T., Bachke, S., Gilljam, K.M., V\u00e5tsveen, T.K., R\u00f8, T.B., Bellacchio, E., Sundan, A., and Otterlei, M. (2013). Targeting Proliferating Cell Nuclear Antigen and Its Protein Interactions Induces Apoptosis in Multiple Myeloma Cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0070430"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Horton, N.C., Mathew, S.O., and Mathew, P.A. (2013). Novel interaction between proliferating cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell function through NKp44. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059552"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nrc3603","article-title":"The roles of TGF\u03b2 in the tumour microenvironment","volume":"13","author":"Pickup","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fimmu.2020.00073","article-title":"Tumor Microenvironment-Associated Extracellular Matrix Components Regulate NK Cell Function","volume":"11","author":"Rossi","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/leu.2011.239","article-title":"NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice","volume":"26","author":"Chen","year":"2012","journal-title":"Leukemia"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e1330235","DOI":"10.1080\/2162402X.2017.1330235","article-title":"NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors","volume":"6","author":"MacFarlane","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3324\/haematol.2013.087536","article-title":"Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia","volume":"99","author":"Stringaris","year":"2014","journal-title":"Haematologica"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2020009871","article-title":"Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia","volume":"138","author":"Duault","year":"2021","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1038\/s41467-020-16447-7","article-title":"MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies","volume":"11","author":"Swaminathan","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1172\/JCI85413","article-title":"MicroRNA-29b mediates altered innate immune development in acute leukemia","volume":"126","author":"Scoville","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3389\/fimmu.2019.01205","article-title":"Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities","volume":"10","author":"Hu","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00262-018-2223-z","article-title":"Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma","volume":"67","author":"Albertini","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1532\/IJH97.04152","article-title":"Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia","volume":"81","author":"Tanaka","year":"2005","journal-title":"Int. J. Hematol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1182\/blood-2012-06-437558","article-title":"A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission","volume":"120","author":"Vey","year":"2012","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/00003081-200209000-00033","article-title":"Leukemias","volume":"45","author":"Pejovic","year":"2002","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_111","first-page":"2634","article-title":"Phase IB\/II Study of Lirilumab with Azacytidine (AZA) in Relapsed AML","volume":"130","author":"Daver","year":"2017","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.3324\/haematol.2019.226696","article-title":"Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients","volume":"105","author":"Tanaka","year":"2020","journal-title":"Haematologica"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells","volume":"175","author":"Denis","year":"2018","journal-title":"Cell"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00262-016-1792-y","article-title":"Selection and expansion of natural killer cells for NK cell-based immunotherapy","volume":"65","author":"Becker","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1182\/blood-2015-12-629055","article-title":"Exploitation of natural killer cells for the treatment of acute leukemia","volume":"127","author":"Handgretinger","year":"2016","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood-2017-08-752170","article-title":"Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation","volume":"131","author":"Cooley","year":"2018","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","article-title":"Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation","volume":"94","author":"Ruggeri","year":"1999","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/eji.201747134","article-title":"NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD","volume":"48","author":"Chan","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fimmu.2016.00144","article-title":"Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell Transplantation","volume":"7","author":"Ullah","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"100678","DOI":"10.1016\/j.blre.2020.100678","article-title":"Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies","volume":"44","author":"Tanaka","year":"2020","journal-title":"Blood Rev."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.4049\/jimmunol.0902598","article-title":"NK Cell Regulation of CD4 T Cell-Mediated Graft-versus-Host Disease","volume":"184","author":"Rivas","year":"2010","journal-title":"J. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2003-12-4438","article-title":"Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells","volume":"104","author":"Igarashi","year":"2004","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Hattori, N., and Nakamaki, T. (2019). Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092057"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.it.2018.04.009","article-title":"NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia","volume":"39","author":"Locatelli","year":"2018","journal-title":"Trends Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.bbmt.2014.01.031","article-title":"Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: A dose-escalation study","volume":"20","author":"Choi","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"596134","DOI":"10.3389\/fonc.2020.596134","article-title":"Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"10","author":"Antar","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40425-019-0564-6","article-title":"A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia","volume":"7","author":"Nguyen","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: From basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"27764","DOI":"10.18632\/oncotarget.8526","article-title":"A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e1119354","DOI":"10.1080\/2162402X.2015.1119354","article-title":"Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival","volume":"5","author":"Burger","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.21873\/anticanres.12824","article-title":"Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells","volume":"38","author":"Murakami","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"673276","DOI":"10.3389\/fonc.2021.673276","article-title":"CAR-NK Cell: A New Paradigm in Tumor Immunotherapy","volume":"11","author":"Marofi","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4049\/jimmunol.1701155","article-title":"Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy","volume":"200","author":"Srivastava","year":"2018","journal-title":"J. Immunol."},{"key":"ref_140","first-page":"1975","article-title":"Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant","volume":"10","author":"Liu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric Antigen Receptor\u2013Modified T Cells for Acute Lymphoid Leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3389\/fimmu.2017.00654","article-title":"Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an \u201cOff-the-Shelf Immunotherapy\u201d for Improvement in Cancer Treatment","volume":"8","author":"Oberschmidt","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10975","article-title":"Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine\u2019","volume":"484","author":"Levin","year":"2012","journal-title":"Nature"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","article-title":"Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity","volume":"8","author":"Zhang","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"611163","DOI":"10.3389\/fimmu.2020.611163","article-title":"Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology","volume":"11","author":"Schmidt","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.omto.2021.10.001","article-title":"The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy","volume":"23","author":"Fabian","year":"2021","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.21873\/anticanres.14543","article-title":"Human NK-92 Cells Function as Target Cells for Human NK Cells\u2013Implications for CAR NK-92 Therapies","volume":"40","author":"Bergman","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/bloodadvances.2019000699","article-title":"Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing","volume":"4","author":"Smith","year":"2020","journal-title":"Blood Adv."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current Perspectives on \u201cOff-The-Shelf\u201d Allogeneic NK and CAR-NK Cell Therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fimmu.2017.00329","article-title":"Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications","volume":"8","author":"Sarvaria","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"18729","DOI":"10.1038\/s41598-019-55239-y","article-title":"Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells","volume":"9","author":"Herrera","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.3389\/fimmu.2020.561553","article-title":"Umbilical Cord Blood and iPSC-Derived Natural Killer Cells Demonstrate Key Differences in Cytotoxic Activity and KIR Profiles","volume":"11","author":"Goldenson","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e26527","DOI":"10.4161\/onci.26527","article-title":"Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity","volume":"2","author":"Boissel","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00262-007-0383-3","article-title":"Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells","volume":"57","author":"Uherek","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","article-title":"A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy","volume":"28","author":"Pomeroy","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e20201529","DOI":"10.1084\/jem.20201529","article-title":"A robust platform for expansion and genome editing of primary human natural killer cells","volume":"218","author":"Huang","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.canlet.2011.01.020","article-title":"Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells","volume":"303","author":"Kellner","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1158\/1078-0432.CCR-13-0505","article-title":"Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition","volume":"19","author":"Wiernik","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-136398","article-title":"GTB-3550 TriKE\u2122 for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory\/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts","volume":"136","author":"Warlick","year":"2020","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2012.87","article-title":"Natural killer cell immune escape in acute myeloid leukemia","volume":"26","author":"Lion","year":"2012","journal-title":"Leukemia"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/eji.200838733","article-title":"Functional role of human NK cell receptor 2B4 (CD244) isoforms","volume":"39","author":"Mathew","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.3389\/fimmu.2018.02809","article-title":"The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment","volume":"9","author":"Agresta","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bbrc.2007.01.176","article-title":"Human natural killer cell receptor 2B4 (CD244) down-regulates its own expression by reduced promoter activity at an Ets element","volume":"355","author":"Mathew","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.imbio.2012.12.002","article-title":"The effect of alloferon on the enhancement of NK cell cytotoxicity against cancer via the up-regulation of perforin\/granzyme B secretion","volume":"218","author":"Bae","year":"2013","journal-title":"Immunobiology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1158\/1078-0432.CCR-08-2810","article-title":"2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells","volume":"15","author":"Altvater","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.4049\/jimmunol.179.7.4672","article-title":"CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes","volume":"179","author":"Lee","year":"2007","journal-title":"J. Immunol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"ref_175","first-page":"1637","article-title":"CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma","volume":"7","author":"Malaer","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","article-title":"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-\u03b1 pathways","volume":"64","author":"Balasa","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: Evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"e1339853","DOI":"10.1080\/2162402X.2017.1339853","article-title":"The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms","volume":"6","author":"Pazina","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e28147","DOI":"10.4161\/onci.28147","article-title":"Are natural killer cells superior CAR drivers?","volume":"3","author":"Klingemann","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1080\/10428194.2019.1623887","article-title":"Strong expression of SLAMF7 in natural killer\/T-cell lymphoma and large granular lymphocyte leukemia\u2014A prominent biomarker and potential target for anti-SLAMF7 antibody therapy","volume":"60","author":"Elmaagacli","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-3083.2009.02367.x","article-title":"LLT1-mediated activation of IFN-gamma production in human natural killer cells involves ERK signalling pathway","volume":"71","author":"Bambard","year":"2010","journal-title":"Scand. J. Immunol."},{"key":"ref_182","first-page":"1050","article-title":"Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells","volume":"8","author":"Marrufo","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"68650","DOI":"10.18632\/oncotarget.11896","article-title":"Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction","volume":"7","author":"Mathew","year":"2016","journal-title":"Oncotarget"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/843\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:15:56Z","timestamp":1760134556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":183,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030843"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030843","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,8]]}}}